Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9110, USA.
Curr Opin Urol. 2012 Sep;22(5):379-84. doi: 10.1097/MOU.0b013e328355ecf5.
To provide an overview of the current research on renal tissue ablation, highlighting novel ablation techniques and technologies.
As long-term data on renal radio frequency ablation (RFA) and cryoablation confirming their oncologic efficacy emerge, ongoing research aims at improving the treatment profiles of these techniques as well as developing novel methods for renal tissue ablation.
Although nephron-sparing surgery is the gold standard treatment for small renal masses confirmed malignant, ablative therapies are an option in elderly patients, who may be poor surgical candidates. RFA and cryoablation have each been used for renal tissue ablation for over a decade but their efficacy in ablation of central lesions or lesions more than 3 cm in size is limited. Increasing ablation size and improving efficiency of thermal energy delivery are the goals of research in RFA and cryoablation. Novel ablation technologies including microwave ablation, irreversible electroporation and high-intensity focused ultrasound among others have undergone preliminary preclinical and clinical evaluation in select series but require further development and assessment of outcomes prior to routine clinical use for renal tumor ablation.
提供目前肾脏组织消融研究的概述，重点介绍新的消融技术和技术。
随着长期关于肾脏射频消融 (RFA) 和冷冻消融的肿瘤疗效数据的出现，目前的研究旨在改善这些技术的治疗效果，并开发新的肾脏组织消融方法。
尽管保留肾单位手术是小肾肿瘤确认恶性肿瘤的金标准治疗方法，但对于可能不适合手术的老年患者，消融治疗是一种选择。RFA 和冷冻消融术已分别用于肾脏组织消融超过十年，但它们在消融中央病变或大于 3 厘米的病变方面的疗效有限。增加消融范围和提高热能传递效率是 RFA 和冷冻消融术研究的目标。包括微波消融、不可逆电穿孔和高强度聚焦超声等新的消融技术在一些系列中已经进行了初步的临床前和临床评估，但在常规临床用于肾肿瘤消融之前，需要进一步开发和评估结果。
